HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 349583Generated: October 29, 2026
Sodium Iodide → (6R,7R)-3-[[5-amino-4-(3-aminopropyl)-1-methylpyrazol-2-ium-2-yl]methyl]-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
https://huagongshe.com/reaction/349583

Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Sodium Iodide | HCID 5238 | — |
| Reactant | Ethyl Acetate | HCID 8857 | — |
| Reactant | tert-butyl 3-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]propylcarbamate | HCID 11634672 | — |
| Reactant | benzhydryl (6R,7R)-3-(chloromethyl)-7-[[(2Z)-2-[2-methyl-1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]oxyimino-2-[5-[(2-methylpropan-2-yl)oxycarbonylamino]-1,2,4-thiadiazol-3-yl]acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate | HCID 87787063 | — |
| Solvent | Water | HCID 962 | — |
| Solvent | Dimethylformamide | HCID 6228 | — |
| Solvent | Dichloromethane | HCID 6344 | — |
| Product | (6R,7R)-3-[[5-amino-4-(3-aminopropyl)-1-methylpyrazol-2-ium-2-yl]methyl]-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate | HCID 141601020 | 20.3% |
Reaction Steps
To a suspension of a mixture of benzhydryl 7β-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate (40 g) and sodium iodide (8 g) in N,N-dimethylformamide (120 ml) and methylene chloride (80 ml) was added tert-butyl 3-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]propylcarbamate (60 g), and the mixture was stirred at room temperature for 16 hours. The reaction mixture was added to a mixture of ethyl acetate and water. The organic layer was separated and dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was evaporated to about 20 ml under reduced pressure. The concentrate was poured into diisopropyl ether (150 ml), and the resulting precipitate was collected by filtration and dried in vacuo. The precipitate was purified by column chromatography on Diaion® PA306 (Mitsubishi Chemical Corporation) TFA form (400 ml) eluting with tetrahydrofuran. The eluate was concentrated in vacuo. The residue was dissolved in methylene chloride (200 ml), and to the solution were added anisole (70 ml) and trifluoroacetic acid (140 ml). The mixture was stirred at room temperature for 3 hours and poured into diisopropyl ether. The resulting precipitate was collected by filtration and dried in vacuo. The obtained powder was dissolved in a phosphate buffer (pH 7) and adjusted to about pH 6 with saturated aqueous sodium hydrogencarbonate solution. The solution containing the objective compound was purified by preparative HPLC utilizing ODS column. The eluate containing a desired product was concentrated in vacuo. The concentrate was adjusted to about pH 1 with concentrated hydrochloric acid and chromatographed on Diaion® HP-20 (Mitsubishi Chemical Corporation) eluting with 20% aqueous 2-propanol. The eluate was evaporated in vacuo and lyophilized to give 7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-[3-amino-4-(3-aminopropyl)-2-methyl-1-pyrazolio]methyl-3-cephem-4-carboxylate (6.1 g).
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US07179801B2 |
|---|
| Source dataset | uspto-grants-2007_02 |
|---|
| ORD ID | ord-2fc8bb6e46a84a91a34c73cab1fd5d5d |
|---|
| Source note | uspto-grants-2007_02 |
|---|